What is sermorelin?
A peptide prescribed in longevity and wellness programmes. For an operator the questions that matter are catalog legitimacy, refill cadence and how carefully the marketing is written.
Key takeaways
- Sermorelin is a peptide prescribed within longevity and wellness protocols by licensed providers.
- It is dispensed through licensed compounding pharmacies, not sold as a supplement.
- Refill cadence is typically longer than GLP-1: an initial review then roughly twelve-week cycles.
- The category's regulatory exposure comes primarily from marketing claims, not the clinical workflow.
- Research-use-only positioning is a different activity and should not be mixed into a prescription business.
What it is
Sermorelin is a peptide used within longevity, recovery and wellness protocols. In telehealth it is prescribed by a provider licensed in the patient's state and prepared by a licensed compounding pharmacy.
It is a prescription item, not a supplement, and the distinction matters commercially as well as legally: a prescription workflow requires genuine provider review, an audit trail and pharmacy licensure at every step.
How the programme runs operationally
Sermorelin protocols typically follow a goal-based intake rather than a diagnosis-led one. The patient arrives with an objective such as recovery, sleep or energy, and the intake translates that into history, current medications, contraindications and consent for provider review.
The cadence is lighter than GLP-1. Commonly an initial four-week review after the first fill, then twelve-week refill cycles, each gated on a check-in reporting tolerance and response.
The catalog discipline question
This is where peptide programmes succeed or fail. Only compounds that are legally prescribable through licensed compounding pharmacies belong in the storefront.
Anything positioned as research-use-only is a different activity with a different risk profile, and mixing the two contaminates the legitimate side of the business. If a compound cannot be prescribed and dispensed properly, it should not be offered.
The claims problem
FTC claim substantiation exposure in this category typically exceeds the clinical risk, because the workflow is comparatively easy to get right and the copy is comparatively easy to get wrong.
Longevity, performance and anti-aging language invites outcome claims that require substantiation. Have the storefront reviewed against FTC and ad-platform standards by someone who did not write it, before launch rather than after a complaint.
Prescribable compounds, real review, LegitScript at $0
PharmaBro supports only legally prescribable compounds through licensed compounding pharmacies, requires provider review on every order with no auto-approve path, and gates refills on a provider-approved check-in.
LegitScript certification is included at $0, which in a scrutinised category is what keeps an ad account alive.
Conclusion
Sermorelin is a straightforward prescription item within a category that attracts disproportionate scrutiny.
Get the catalog right, keep provider review genuine, gate the refill on a check-in, and treat the marketing copy as the primary risk surface rather than an afterthought.
Frequently asked questions
Is sermorelin a prescription medication?
In a telehealth context it is prescribed by a licensed provider and dispensed by a licensed compounding pharmacy. It is not a supplement, and treating it as one is the mistake that creates regulatory exposure.
How often do sermorelin patients reorder?
Typically an initial four-week review after the first fill, then roughly twelve-week refill cycles, with each renewal approved by the reviewing provider after a check-in.
What is the biggest risk in offering it?
Marketing claims. FTC substantiation exposure in peptide and longevity categories typically exceeds the clinical risk, so storefront copy should be reviewed against FTC and ad-platform standards before launch.
Priya RaghunathanHead of Compliance Operations
Handles LegitScript, HIPAA posture, MSO structuring and state coverage. Writes the parts of this blog that operators wish someone had told them before they signed.